celecoxib oral

P=N/A, N=50, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University

P=N/A, N=60, Completed, Affiliated Hospital of Jining Medical University; Affiliated Hospital of Jining Medical University

P2, N=39, Recruiting, Emory University | Not yet recruiting --> Recruiting

P1, N=60, Not yet recruiting, University of Pennsylvania | Trial completion date: May 2028 --> Nov 2028 | Trial primary completion date: May 2027 --> Jan 2028

COX-2 is a critical early-event biomarker and therapeutic target in colorectal adenomas. Targeting the COX-2 pathway represents a viable strategy for prevention, although challenges regarding safety and personalized application remain.

P1, N=200, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.

P1, N=6, Active, not recruiting, HonorHealth Research Institute | Recruiting --> Active, not recruiting | N=18 --> 6 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Jun 2026

Rats were administered OANG (high/low dose) intra-articularly, with celecoxib as a positive control...Furthermore, OANG ameliorated hippocampal oxidative stress and inflammation (decreased Cleaved caspase-3, Malondialdehyde; increased IL-10). Network pharmacology and docking suggested the involvement of peroxisome proliferator-activated receptor gamma, mitogen-activated protein kinase 3, prostaglandin-endoperoxide synthase 2, and pathways such as estrogen signaling and cyclic adenosine monophosphate signaling.

This study investigates the in vitro antitumor properties and mechanism of action of novel vicinal diaryl-substituted heterocyclic COX-2 inhibitors, with a focus on VA1213, in comparison to celecoxib, a widely marketed COX-2 inhibitor known for its off-target effects...Its ability to interfere with multiple cancer-associated signaling pathways and reduce tumor cell aggressiveness underscores its potential as a promising therapeutic candidate. Further in vivo studies are warranted to confirm its efficacy and assess potential off-target effects.

Docking analysis results demonstrated that compounds 1, 2, 4, and 5 had the capacity to occupy the catalytic domain of COX-2 enzymes, exhibiting analogous binding conformations to those observed with the selective COX-2 inhibitor celecoxib. All these findings implied that these di/trinormonoterpenoid glucosides derived from PC possess promising characteristics for development as novel COX-2-targeted therapeutic agents.

P1, N=15, Recruiting, C17 Council | Not yet recruiting --> Recruiting | Trial completion date: Sep 2032 --> Dec 2032 | Trial primary completion date: Sep 2030 --> Dec 2030

P2, N=4, Completed, Leidos Life Sciences | Active, not recruiting --> Completed | N=2000 --> 4